Radiation therapy induces innate immune responses in patients treated for prostate cancers.
Amrita K CheemaYaoxiang LiMary VentimigliaKeith J KowalczykRyan HankinsGaurav BandiEinsley-Marie JanowskiScott GrindrodAlejandro VillagraAnatoly DritschiloPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
To our knowledge, these data are the first report of longitudinal proteomic and metabolomic molecular responses in patients after radiation therapy for cancers. The data supports innate immune activation as a critical clinical response of patients receiving radiation therapy for prostate cancer. Furthermore, we propose that the observed IIR may be generalized to the treatment of other cancer types, potentially informing multidisciplinary therapeutic strategies for cancer treatment.
Keyphrases
- innate immune
- prostate cancer
- radiation therapy
- end stage renal disease
- electronic health record
- radical prostatectomy
- ejection fraction
- healthcare
- newly diagnosed
- big data
- peritoneal dialysis
- papillary thyroid
- prognostic factors
- squamous cell carcinoma
- quality improvement
- benign prostatic hyperplasia
- replacement therapy
- deep learning
- artificial intelligence
- squamous cell
- combination therapy
- lymph node metastasis